ZeTox

BY
OUR
PLATFORMS

icon-developmental-tox-and-teratogenicity DevTox

Our Developmental Toxicity and Teratogenicity assay allows a better prediction and description of the teratogenic impact than a Fast Acute Tox assay. The broader number of phenotypes tested and the accurate quantification of subtle morphometric changes provides an integral teratogenic profile of your candidate chemical.

Method description

The assay is divided in two phases, allowing the precise determination of the concentration rage in which the molecule promotes mortality and teratogenicity.

Phase I

Incubation of embryos with 5 different concentrations in a logarithmic progression of the molecule of interest based on OECD guidelines.

Determination of LOEC and LC50 values at 24 and 96 hpf, and benchmark dose (BMD) values at 96 hpf.

BMD values will be used to determine the new range of concentration to be tested in Phase 2.

Phase II

Incubation of embryos – single embryo exposure – with the molecule of interest is performed at 5 concentrations established upon Phase I results.

Determination of LOEC and LC50 values at 24 and 96 hpf, and AC50s values for each teratogenic phenotype at 96 hpf.

LC50 and AC50 (for the most sensitive phenotype) will be used to obtain the Teratogenic Index (TI) for each compound of interest.

Figure: Representative photos of zebrafish embryos exposed to DEAB at 2 different concentrations. Negative control E3+DMSO1% (a); dose-response curves at 96 hpf (b)